Cantor Fitzgerald Initiates Coverage on Keros Therapeutics (NASDAQ:KROS)

Cantor Fitzgerald began coverage on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating on the stock.

Several other research analysts also recently commented on the stock. Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price objective for the company. Bank of America lowered their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Finally, Guggenheim initiated coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a "buy" rating and a $96.00 price objective on the stock. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics has a consensus rating of "Buy" and an average target price of $89.11.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $1.57 during mid-day trading on Thursday, reaching $59.56. The company had a trading volume of 366,465 shares, compared to its average volume of 369,702. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -11.55 and a beta of 1.23. The business's 50-day simple moving average is $54.33 and its 200 day simple moving average is $51.94. Keros Therapeutics has a one year low of $27.02 and a one year high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the prior year, the company posted ($1.27) earnings per share. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.88 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the business's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares in the company, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.90% of the company's stock.

Institutional Trading of Keros Therapeutics

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics during the third quarter worth about $89,000. Assenagon Asset Management S.A. raised its position in shares of Keros Therapeutics by 814.6% during the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock worth $12,990,000 after acquiring an additional 199,245 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Keros Therapeutics by 21.3% in the third quarter. Handelsbanken Fonder AB now owns 9,700 shares of the company's stock worth $563,000 after acquiring an additional 1,700 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics in the second quarter valued at approximately $128,000. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.